Benzoxazinone Amides for Selective MR Modulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for cardiovascular, inflammatory, metabolic, and renal conditions, such as heart failure, hypertension, chronic kidney disease, and diabetic nephropathy, often face limitations due to toxicity, side effects, and pharmacokinetic issues with existing mineralocorticoid receptor (MR) antagonists, particularly concerning hyperkalemia risk.
Innovation Solution
Development of novel benzoxazinone amides and their pharmaceutically acceptable salts as potent and selective MR modulators, which act as competitive aldosterone binders with improved efficacy, reduced toxicity, and enhanced pharmacokinetic profiles, including higher oral bioavailability and lower clearance.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing MR antagonists are used to treat cardiovascular and renal conditions, then endothelial dysfunction is improved, but hyperkalemia risk increases
Solution Approach 1:
The patent modifies the chemical structure of MR antagonists by introducing specific substituents (R1 and R2 groups) and molecular weight constraints (150-500 Da) to change the pharmacokinetic parameters. These structural changes result in compounds with improved oral bioavailability (20-80%) and reduced clearance (5-50 mL/min), thereby reducing the dose required to achieve therapeutic effect and consequently lowering hyperkalemia risk while maintaining endothelial protection
Solution Approach 2:
The patent introduces selective targeting of the mineralocorticoid receptor in vascular endothelium through specific molecular design. The compounds exhibit preferential binding to MR in endothelial cells compared to renal epithelial cells, achieving local therapeutic effect in the vasculature while minimizing systemic side effects like hyperkalemia. This selectivity is achieved through optimization of hydrophobic interactions and hydrogen bonding capabilities at specific molecular regions
2Reliability
If MR antagonists are administered to achieve therapeutic effects, then cardiovascular benefits are obtained, but toxicity and side effects increase
Solution Approach 1:
The patent designs MR antagonists with optimized metabolic stability to achieve appropriate half-life duration for sustained cardiovascular protection without accumulating to toxic levels. The compounds are structurally designed to be metabolized through conventional pathways after exerting their therapeutic effect, avoiding long-term persistence and chronic toxicity. This approach allows repeated dosing with maintained safety margin
Solution Approach 2:
The patent incorporates protective structural features in the MR antagonist molecules that prevent off-target binding to other receptors and enzymes. The specific substitution patterns on the benzoxazinone core provide steric and electronic protection against unwanted interactions, thereby preventing potential toxic effects before they can occur. This preliminary protective design reduces the need for dose reduction and improves the therapeutic index
3Reliability
If conventional MR antagonists are used, then mineralocorticoid blockade is achieved, but pharmacokinetic profile is suboptimal
Solution Approach 1:
The patent systematically varies key pharmacokinetic parameters through structural optimization. Molecular weight is constrained to 150-500 Da to balance membrane permeability and solubility. Lipophilicity is tuned through selection of hydrophobic substituents (aryl, heteroaryl groups) to achieve optimal absorption without excessive protein binding. These parameter optimizations collectively improve oral bioavailability to 20-80% range and reduce clearance to 5-50 mL/min, achieving superior pharmacokinetic profile compared to conventional agents
Solution Approach 2:
The patent creates composite molecular structures combining the benzoxazinone core with diverse substituent groups (amides, esters, heteroaryl moieties). This composite design allows integration of multiple functional properties: the core provides MR binding affinity, while attached groups contribute to solubility, metabolic stability, and pharmacokinetic optimization. The synergistic combination of these structural elements achieves both high efficacy and improved pharmacokinetics
Data Source
Figure 1
AI summary
Disclosed arecertain derivatives of benzoxazinone amidesof formula (I),or pharmaceutically acceptable salts thereof, (Formula (I)) that act as mineralocorticoid (MR) receptor modulatorsthat may reduce oxidative stress in endothelium and hence improve vascular function, to methods for their potential therapeutic use, to pharmaceutical compositions containing them and to processes for preparing such compounds.